<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Edoxaban: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Edoxaban: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Edoxaban: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="99504" href="/d/html/99504.html" rel="external">see "Edoxaban: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26821772"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Reduced efficacy in nonvalvular atrial fibrillation patients with CrCl &gt;95 mL/minute:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Edoxaban should not be used in patients with CrCl &gt;95 mL/minute. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCl &gt;95 mL/minute had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Premature discontinuation of edoxaban increases the risk of ischemic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Spinal/Epidural hematomas:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Epidural or spinal hematomas may occur in patients treated with edoxaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:</p>
<p style="text-indent:-2em;margin-left:4em;">- use of indwelling epidural catheters</p>
<p style="text-indent:-2em;margin-left:4em;">- concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants</p>
<p style="text-indent:-2em;margin-left:4em;">- a history of traumatic or repeated epidural or spinal punctures</p>
<p style="text-indent:-2em;margin-left:4em;">- a history of spinal deformity or spinal surgery</p>
<p style="text-indent:-2em;margin-left:4em;">- optimal timing between the administration of edoxaban and neuraxial procedures is not known</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefits and risks before neuraxial intervention in patients who are anticoagulated or are to be anticoagulated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26930479"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Savaysa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871877"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lixiana</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26821773"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Factor Xa Inhibitor;</li>
<li>
                        Direct Oral Anticoagulant (DOAC)</li></ul></div>
<div class="block doa drugH1Div" id="F26979880"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The adult dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editor: Edith A Nutescu, PharmD, MS, FCCP.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="672f8223-616d-4432-bc3d-b11157e2f21b">Nonvalvular atrial fibrillation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with nonvalvular atrial fibrillation (AF) and CrCl &gt;95 mL/minute, the efficacy of edoxaban for prevention of ischemic stroke was decreased. Do not use edoxaban for nonvalvular AF if CrCl is &gt;95 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27358434','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27358434','lexi-content-ref-manu.1'])">Ref</a></span>) [recommendations may vary in international labeling]. Dosage reductions for kidney impairment are listed under "Dosing: Altered Kidney Function: Adult."</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patient weight &gt;60 kg: </i>
<b>Oral: </b>60 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24251359','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24251359','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patient weight ≤60 kg:</i>
<b>Oral:</b> 30 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24251359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24251359'])">Ref</a></span>). Some experts only recommend this dose adjustment in patients who are also ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manning.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manning.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Post-percutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Administer with an appropriate antithrombotic regimen including clopidogrel (preferred P2Y12 inhibitor in this situation) with or without aspirin, depending on risks for thrombosis and bleeding and time since percutaneous coronary intervention (PCI) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-32176890','lexi-content-ref-31492505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-32176890','lexi-content-ref-31492505'])">Ref</a></span>). It is recommended to discontinue aspirin 1 to 4 weeks after PCI and continue edoxaban and clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>). In the clinical trial, use of edoxaban plus clopidogrel did not demonstrate a reduced risk of bleeding compared to a regimen including a vitamin K antagonist, aspirin, plus clopidogrel, although efficacy between treatment groups was similar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient weight &gt;60 kg:</i>
<b>Oral</b>: 60 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492505','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492505','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient weight ≤60 kg:</i>
<b>Oral:</b> 30 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492505'])">Ref</a></span>). Some experts only recommend this dose adjustment in patients who are also ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manning.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manning.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e773a39f-176a-42f9-b942-8ed646b3aec0">Venous thromboembolism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Deep vein thrombosis and/or pulmonary embolism treatment</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used in patients with active cancer (eg, metastatic disease or receiving chemotherapy); however, avoid use in patients with upper GI tract cancers due to increased bleeding risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-31381464','lexi-content-ref-29231094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-31381464','lexi-content-ref-29231094'])">Ref</a></span>). Prior to initiation of edoxaban, assess CrCl using the Cockcroft-Gault equation. Some experts recommend <b>not</b> using edoxaban for venous thromboembolism (VTE) treatment if CrCl is &gt;95 mL/minute, although specific data regarding an increased risk of recurrent VTE are lacking in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1'])">Ref</a></span>). Dosage reductions for kidney impairment are listed under Dosing: Altered Kidney Function: Adult.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> After at least 5 days of initial therapy with a parenteral anticoagulant, transition to edoxaban in hemodynamically stable patients:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient weight &gt;60 kg: </i>60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patient weight ≤60 kg:</i> 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapeutic anticoagulation (first episode, general recommendations):</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences:</p>
<p style="text-indent:-2em;margin-left:8em;">Provoked venous thromboembolism: 3 months, provided provoking risk factor is no longer present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Unprovoked venous thromboembolism or provoked venous thromboembolism with a persistent risk factor: ≥3 months depending on risk of VTE recurrence and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-22332937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-22332937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between anticoagulants</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to edoxaban:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from low-molecular-weight heparin or fondaparinux (therapeutic dose) to edoxaban:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>General transition recommendation: </i>Initiate edoxaban at the time of the next scheduled dose of the parenteral anticoagulant.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Venous thromboembolism initial treatment transition (alternative recommendation):</i> For acute VTE, some experts start edoxaban within 6 to 12 hours after the last dose of a twice-daily LMWH regimen and within 12 to 24 hours after a once-daily regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from unfractionated heparin continuous infusion to edoxaban:</b> Initiate edoxaban when the unfractionated heparin continuous infusion is stopped (consult local protocol if aPTT is above target range) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from warfarin to edoxaban:</b> Discontinue warfarin and initiate edoxaban as soon as INR falls to ≤2.5 (US labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from edoxaban to another anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from edoxaban to parenteral anticoagulant:</b> Start the parenteral anticoagulant when the next dose of edoxaban was scheduled to be given.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning from edoxaban to warfarin:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Oral option</i>: For patients taking edoxaban 60 mg once daily, reduce the dose to 30 mg once daily and begin warfarin concomitantly. For patients taking edoxaban 30 mg once daily, reduce the dose to 15 mg once daily and begin warfarin concomitantly. Measure INR at least weekly and just prior to the daily dose of edoxaban to minimize influence of edoxaban on INR measurements. Discontinue edoxaban once a stable INR ≥2 is achieved; continue warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Parenteral option</i>: Discontinue edoxaban and initiate a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Discontinue the parenteral anticoagulant once a stable INR ≥2 is achieved; continue warfarin.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transitioning between direct oral anticoagulants:</b> Start new direct oral anticoagulant (DOAC) when next dose of previous DOAC was scheduled to be given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991563"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Calculate CrCl using the Cockcroft-Gault equation. In patients who develop acute kidney injury during use, closely monitor or consider switching to an alternative anticoagulant due to an increased risk of bleeding in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28167634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28167634'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis and/or pulmonary embolism, treatment</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function</b>:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary. <b>Note:</b> Some experts recommend <b>not</b> using edoxaban for VTE treatment if CrCl is &gt;95 mL/minute although specific data regarding an increased risk of recurrent VTE is lacking in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 50 mL/minute: Oral: 30 mg once daily. <b>Note:</b> Patients with CrCl &lt;30 mL/minute (as determined by Cockcroft-Gault equation) at baseline were excluded from the Hokusai-VTE trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23991658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23991658'])">Ref</a></span>) and from the VTE trial in cancer patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29231094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29231094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25566930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25566930'])">Ref</a></span>): Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;95 mL/minute: Use is not recommended due to increased risk of ischemic stroke compared to warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27358434','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27358434','lexi-content-ref-manu.1'])">Ref</a></span>) [recommendations may vary in international labeling].</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 to 95 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 50 mL/minute: Oral: 30 mg once daily. <b>Note:</b> Patients with CrCl &lt;30 mL/minute (as determined by Cockcroft-Gault equation) at baseline were excluded from the ENGAGE AF-TIMI 48 trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24251359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24251359'])">Ref</a></span>). However, a post-hoc analysis suggested that for subjects whose CrCl fell below 30 mL/minute during the trial, stroke and major bleeding rates in patients receiving edoxaban 30 mg once daily were similar to those in patients treated with warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). Additionally, a small, retrospective observational study similarly suggested efficacy and safety of edoxaban 30 mg once daily in patients with CrCl between 15 and &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30191509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30191509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30686041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25566930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25566930'])">Ref</a></span>). Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30686041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988620"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B and C): Use is not recommended.</p></div>
<div class="block doo drugH1Div" id="F46859511"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of edoxaban (and other direct oral anticoagulants [DOACs]) in patients with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg due to the lack of clinical data in this population. If used in a patient with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, ISTH suggests measuring peak and trough levels using an anti-factor Xa assay or mass spectrometry. If drug level is below the expected range, ISTH suggests changing to a vitamin K antagonist rather than adjusting the dose of edoxaban (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27299806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27299806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">For bariatric and other GI surgery patients, evaluate the risk versus benefit of possible decreased drug absorption. Edoxaban tablets disintegrate in the stomach, which is dependent on an acidic environment. Absorption primarily occurs in the proximal small intestine. Surgeries which raise the pH of the stomach (eg, Roux-en-Y gastric bypass) or decrease small intestine sites may decrease absorption of edoxaban (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28050755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28050755'])">Ref</a></span>). The available data are conflicting for absorption alterations, derived from small populations, and underrepresent individual DOACs and distinct surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28121368','lexi-content-ref-30396779','lexi-content-ref-30546740','lexi-content-ref-29157916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28121368','lexi-content-ref-30396779','lexi-content-ref-30546740','lexi-content-ref-29157916'])">Ref</a></span>). Since there is no established correlation between target blood levels of DOACs with efficacy, therapeutic drug monitoring is difficult. Consider alternative anticoagulation if there is a need for direct monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28050755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28050755'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F26979881"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with nonvalvular atrial fibrillation (AF) and CrCl &gt;95 mL/minute, the efficacy of edoxaban for prevention of ischemic stroke was decreased. Do not use edoxaban for nonvalvular AF if CrCl is &gt;95 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27358434','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27358434','lexi-content-ref-manu.1'])">Ref</a></span>) [recommendations may vary in international labeling]. Dosage reductions for kidney impairment are listed under "Dosing: Altered Kidney Function: Adult."</p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥80 years of age who are considered to be inappropriate candidates for oral anticoagulants at the approved doses (eg, low body weight [ie, ≤45 kg] <b>or</b> body weight ≤60 kg plus one of the following: severe kidney impairment [eg, CrCl &lt;30 mL/minute], history of GI bleeding or bleeding from a critical area, continuous use of a nonsteroidal anti-inflammatory drug, or concurrent use of an antiplatelet agent):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 15 mg once daily may be considered. <b>Note:</b> Dosing is based on a relatively small, randomized, placebo-controlled trial (n = 984) of elderly Japanese patients ≥80 years of age with low body weight (mean weight: 50.6 kg) and reduced kidney function (mean CrCl = 36.3 mL/minute). The results of this trial may not be applicable to other populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32865374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32865374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Postpercutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism:</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between anticoagulants:</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F27121354"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (7% to 26%), major hemorrhage (1% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal hemorrhage (6%), skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (≤4%), oral hemorrhage (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gross hematuria (≤2%), urethral bleeding (≤2%), vaginal hemorrhage (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (5% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Puncture site bleeding (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (5%), pharyngeal bleeding (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ischemia (with premature discontinuation)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Epidural intracranial hemorrhage (in patients receiving neuraxial anesthesia or undergoing spinal puncture), spinal hematoma (in patients receiving neuraxial anesthesia or undergoing spinal puncture)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney disease</p></div>
<div class="block coi drugH1Div" id="F26821776"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Active pathological bleeding</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to edoxaban or any component of the formulation; conditions at increased risk of significant bleeding (recent hemorrhagic or ischemic cerebral infarction); active peptic ulcer disease with recent bleeding; impaired spontaneous or acquired hemostasis; hepatic disease associated with coagulopathy and clinically relevant bleeding risk; concomitant use with any other anticoagulant such as unfractionated heparin (except at doses used to maintain a patent central venous or arterial catheter), low molecular weight heparins (eg, enoxaparin and dalteparin); heparin derivatives (eg, fondaparinux), oral anticoagulants (eg, warfarin, dabigatran, apixaban, rivaroxaban) except when switching therapy to or from edoxaban; pregnant or breastfeeding women.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F26960764"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: May increase the risk of bleeding, including severe and potentially fatal bleeding. Concomitant use of drugs that affect hemostasis (eg, aspirin, other antiplatelet agents, other antithrombotic agents, fibrinolytic therapy, chronic NSAID use, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors) may increase the risk of bleeding. Discontinue therapy with active pathological hemorrhage and promptly evaluate for bleeding source. Hemodialysis does not have a substantial impact on edoxaban clearance and protamine sulfate, vitamin K, and tranexamic acid are not expected to reverse the anticoagulant effect of edoxaban. Andexanet alfa should be considered for reversal of edoxaban (ACC [Tomaselli 2020]; Baugh 2019; Cuker 2019). Depending on the bleeding severity, activated oral charcoal should be considered if ingestion occurred within 1 to 2 hours of presentation. The following alternative options may also be considered depending on the clinical scenario: 4-factor unactivated prothrombin concentrate (PCC) (eg, Kcentra) or 4-factor activated prothrombin complex concentrate (aPCC) (eg, FEIBA). Some studies and case reports have shown moderate success in correcting coagulation tests with some of these agents; however, correction of coagulation tests does not imply reversal of the anticoagulation effect of the medication (AHA/ASA [Hemphill 2015]; EHRA [Heidbuchel 2015]; NCS/SCCM [Frontera 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant.</b> In patients with non-valvular atrial fibrillation who had an acute ischemic stroke while receiving a direct oral anticoagulant (DOAC) (eg, edoxaban), guidelines generally support withholding oral anticoagulation until 4 to 14 days after the onset of neurological symptoms (time frame may vary with shorter times for transient ischemic attack or small, nondisabling stroke and longer times for moderate to severe stroke) (AHA/ASA [Kernan 2014]; AHA/ASA [Powers 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiphospholipid syndrome: Use not recommended for patients with triple-positive antiphospholipid syndrome (APS). Patients with APS (especially if triple positive for all 3 antiphospholipid antibodies [lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I]) may have increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI/Bariatric surgery: Altered absorption: Evaluate the risk versus benefit of possible decreased drug absorption. Edoxaban tablets disintegrate in the stomach, which is dependent on an acidic environment. Absorption primarily occurs in the proximal small intestine. Surgeries which raise the pH of the stomach (eg, Roux-en-Y gastric bypass) or decrease small intestine sites may decrease absorption of edoxaban (Hakeam 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh class B and C) due to intrinsic coagulation abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nonvalvular atrial fibrillation: <b>[US Boxed Warning]: Do not administer to nonvalvular atrial fibrillation (NVAF) patients with CrCl &gt;95 mL/minute (calculated using the Cockcroft-Gault formula). In clinical trials, these patients had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin; use another anticoagulant in these patients </b>(Bohula 2016; US manufacturer's labeling [recommendations may vary in international labeling]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Dose adjustment is necessary in patients with kidney impairment. In patients who develop acute kidney injury during use, closely monitor or consider switching to an alternative anticoagulant due to an increased risk of bleeding in this population (AHA [Raval 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Valvular disease: Avoid use in patients with surgically implanted mechanical heart valve, transcatheter aortic valve replacement with no other indication for anticoagulation, moderate to severe mitral stenosis, or significant rheumatic heart disease; however, may be used in patients with atrial fibrillation and native aortic valve disease, tricuspid valve disease, mitral regurgitation, or surgical bioprosthetic mitral valve replacement when anticoagulation is required (ACC/AHA [Otto 2021]; AHA/ACC/HRS [January 2014]; AHA/ACC/HRS [January 2019]; Gaasch 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: When temporary interruption is necessary before surgery or a procedure, the timing of discontinuation depends on kidney function and risk for bleeding complications. In patients with CrCl ≥30 mL/minute, discontinue therapy ~24 to 48 hours before surgery, depending on risk for bleeding. In patients with CrCl &lt;30 mL/minute, may consider discontinuing therapy ~48 to 72 hours before surgery, depending on risk for bleeding. Consider discontinuing for a longer period of time in patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. After discontinuation, bridging with low molecular weight heparin or heparin perioperatively is not necessary and may increase risk of bleeding. When there is adequate hemostasis after surgery, may reinstitute therapy after ≥24 hours depending on risk for bleeding. Specific considerations can be found in expert scientific statements and consensus pathways (ACC [Doherty 2017]; ACCP [Douketis 2022]; AHA [Raval 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: In patients with venous thromboembolism (DVT and/or PE) and body weight ≤60 kg, dosage reduction is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Spinal or epidural hematoma: <b>[US Boxed Warning]: Spinal or epidural hematomas resulting in long-term or permanent paralysis may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal/epidural puncture; the risk is increased by the use of indwelling epidural catheters, concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or surgery, or if optimal timing between the administration of edoxaban and neuraxial procedures is not known. Consider the potential benefits and risks prior to neuraxial intervention in patients who are anticoagulated or scheduled to be anticoagulated. Monitor frequently for signs and symptoms of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction). If neurologic impairment is noted, urgent treatment is necessary.</b></p>
<p style="text-indent:-2em;margin-left:6em;">- In patients who receive both edoxaban and neuraxial anesthesia, avoid removal of epidural or intrathecal catheter for at least 12 hours following last edoxaban dose; avoid edoxaban administration for at least 2 hours following catheter removal.</p></div>
<div class="block foc drugH1Div" id="F26930480"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Savaysa: 15 mg, 30 mg, 60 mg</p></div>
<div class="block geq drugH1Div" id="F26930478"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F27265720"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Savaysa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $16.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $16.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $16.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871878"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lixiana: 15 mg, 30 mg, 60 mg</p></div>
<div class="block adm drugH1Div" id="F26979885"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients unable to swallow whole tablets may crush tablets and mix with applesauce or 60 to 90 mL water; administer immediately. For patients with a gastric tube, mix crushed tablets with 60 to 90 mL water and administer immediately.</p></div>
<div class="block meg drugH1Div" id="F45303157"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Savaysa: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F206316s019lbl.pdf%23page%3D35&amp;token=k%2BKRkRIgfGpfRTIrO0DH2p6IpqPx8Nw0CrnbD9JaJ0N%2F8GTyR%2B%2FHmULp9oV19CLtRw9x3CqBboRkeRY6d4ISK1QdMunZh2F1TBVNHjBXaY%2BzGHCNVomdzH9xzu4RnhR7&amp;TOPIC_ID=99275" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206316s019lbl.pdf#page=35</a></p></div>
<div class="block use drugH1Div" id="F26821775"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvalvular atrial fibrillation:</b> To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Do not use in nonvalvular AF patients with CrCl &gt;95 mL/minute because of an increased risk of ischemic stroke compared to warfarin (Bohula 2016; US manufacturer's labeling [recommendations may vary in international labeling]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism (deep vein thrombosis and pulmonary embolism):</b> Treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant.</p></div>
<div class="block mst drugH1Div" id="F26960759"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High-alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, renal function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26868966"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F26868963"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Edoxaban may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.  Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban. Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30mg daily when combined with azithromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce edoxaban dose to 30 mg daily when combined with clarithromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with erythromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with itraconazole. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with oral ketoconazole. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Edoxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May diminish the therapeutic effect of Edoxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Edoxaban. Management: Avoid coadministration of edoxaban and P-glycoprotein (P-gp) inducers if possible. If concomitant use is required, be aware the edoxaban efficacy may be decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Edoxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with quinidine. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Edoxaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Edoxaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Consider avoiding use of sotorasib and narrow therapeutic index/sensitive P-gp substrates. If combined use is unavoidable, monitor for increased toxicities of the substrate and consider a decrease in the substrate dosage.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May increase the serum concentration of Edoxaban. Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with verapamil. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53241196"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy planning is recommended for patients who could become pregnant and require use of direct-acting oral anticoagulants (DOACs). Outcome data related to the use of DOACs during pregnancy are limited; until safety data are available, adequate contraception is recommended during therapy for patients who may become pregnant. Patients planning to become pregnant should be switched to alternative anticoagulants prior to conception (Cohen 2016) or immediately once pregnancy is confirmed (Beyer-Westendorf 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Heavy menstrual bleeding may occur in patients taking DOACs. Evaluate menstrual bleeding patterns prior to therapy in patients with underlying hemorrhagic conditions. Evaluate changes in uterine bleeding. Surgical interventions may be required in patients with abnormal uterine bleeding (Beyer-Westendorf 2021).</p></div>
<div class="block pri drugH1Div" id="F26960761"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data specific to the use of edoxaban in pregnancy are limited (Areia 2022; Beyer-Westendorf 2016; Lameijer 2018; Sakai 2019; Sessa 2019). Use of direct-acting oral anticoagulants (DOACs) increases the risk of bleeding in all patients. When used in pregnancy, there is also the potential for fetal bleeding or subclinical placental bleeding, which may increase the risk of miscarriage, preterm delivery, fetal compromise, or stillbirth (Cohen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Data are insufficient to evaluate the safety of DOACs during pregnancy and use in pregnant patients is not recommended (ACOG 2018; Regitz-Zagrosek [ESC 2018]). Patients should be switched to an alternative anticoagulant if pregnancy occurs during therapy. Fetal monitoring that includes evaluations for fetal bleeding and assessments for risk of preterm delivery are recommended if the DOAC is continued (Cohen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to DOACs during pregnancy is ongoing. Health care providers may enroll patients in the International Registry of Pregnancy During DOAC Use (https://redcap.isth.org/surveys/?s=P99ARFCM3J) (Othman 2019).</p></div>
<div class="block brc drugH1Div" id="F26960763"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if edoxaban is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. Until safety data are available, direct-acting oral anticoagulants are not recommended for use in patients who are breastfeeding; use of an alternative anticoagulant is preferred (ACOG 2018; ASH [Bates 2018]; Cohen 2016).</p></div>
<div class="block mop drugH1Div" id="F26979887"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC, aPTT, PT, serum creatinine, and liver function tests prior to initiation, when clinically indicated, and at least annually (AHA/ACC/HRS [January 2014]; Leung 2019)</p>
<p style="text-indent:-2em;margin-left:2em;">Routine coagulation testing is <b>not</b> required or necessary for direct oral anticoagulants (DOACs). There are currently no FDA-approved assays or calibration reagents available.</p>
<p style="text-indent:-2em;margin-left:2em;">In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings, absorption), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. Most commonly used coagulation tests (PT, INR, aPTT) cannot definitively exclude the presence of clinically relevant serum concentrations. A prolonged PT suggests clinically relevant serum concentrations are present, but normal PT and aPTT values using standard reagents cannot rule out the presence of edoxaban. Highly sensitive reagents for PT testing may be able to exclude the presence of edoxaban.</p>
<p style="text-indent:-2em;margin-left:2em;">If available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is anti-factor Xa activity calibrated specifically for edoxaban (undetectable anti-factor Xa activity likely excludes clinically relevant drug concentrations). An anti-factor Xa assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations but is not useful for quantification (ACC [Tomaselli 2020]; AHA [Raval 2017]; Leung 2019).</p></div>
<div class="block rer drugH1Div" id="F53129463"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">The International Council for Standardization in Haematology (ICSH) provides examples of edoxaban drug levels for the 60 mg once daily dose, with an expected median peak of ~170 to 234 ng/mL (interquartile range of 125 to 317 ng/mL) and an expected median trough of ~19 to 36 ng/mL (interquartile range of 10 to 62 ng/mL) (Gosselin 2018). These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets (Leung 2019).</p></div>
<div class="block pha drugH1Div" id="F26964813"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Edoxaban, a selective factor Xa inhibitor, inhibits free factor Xa and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of factor Xa in the coagulation cascade reduces thrombin generation and thrombus formation.</p></div>
<div class="block phk drugH1Div" id="F26979911"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 107 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~55%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal via hydrolysis, conjugation and oxidation by CYP3A4; predominant metabolite (M-4) is active (&lt;10% of parent compound)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 62%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 10 to 14 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily unchanged); renal clearance: ~50% of total clearance</p></div>
<div class="block phksp drugH1Div" id="F51154009"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Renal impairment: Systemic exposure increased by 32% (CrCl &gt;50 to &lt;80 mL/minute), 74% (CrCl 30 to 50 mL/minute), and 72% (CrCl &lt;30 mL/minute), and 93% (peritoneal dialysis).</p>
<p style="text-indent:-2em;margin-left:2em;">No renal impairment: Edoxaban blood levels are lower in patients with better renal function, averaging about 30% less in patients with CrCl &gt;80 mL/minute and 40% less in patients with CrCl &gt;95 mL/minute when compared to patients with CrCl &gt;50 to ≤80 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Total exposure in patients with low body weight (55 kg) was increased by 13%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27161183"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Roteas</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lixiana | Roteas</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lixiana | Roteas</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Coaguloban</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lixiana | Savaysa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Edoban</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Savaysa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Roteas</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Roteas</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lixiana</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Edoxacord</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi: 10.1111/jgs.15767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 196: Thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35073471">
<a name="35073471"></a>Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy - a systematic review. <i>J Perinat Med</i>. 2022;50(4):457-461. doi:10.1515/jpm-2021-0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/35073471/pubmed" id="35073471" target="_blank">35073471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi: 10.1111/j.1538-7836.2012.04662.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482767">
<a name="30482767"></a>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Adv</i>. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30482767/pubmed" id="30482767" target="_blank">30482767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31732375">
<a name="31732375"></a>Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. <i>Ann Emerg Med</i>. 2020;76(4):470-485. doi:10.1016/j.annemergmed.2019.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/31732375/pubmed" id="31732375" target="_blank">31732375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33977211">
<a name="33977211"></a>Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoagulants. <i>Res Pract Thromb Haemost</i>. 2021;5(4):e12512. doi:10.1002/rth2.12512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/33977211/pubmed" id="33977211" target="_blank">33977211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27384740">
<a name="27384740"></a>Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thromb Haemost</i>. 2016;116(4):651-658. doi:10.1160/TH16-04-0305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27384740/pubmed" id="27384740" target="_blank">27384740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358434">
<a name="27358434"></a>Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i>. 2016;134(1):24-36. doi:10.1161/CIRCULATIONAHA.116.022361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27358434/pubmed" id="27358434" target="_blank">27358434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27346676">
<a name="27346676"></a>Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(8):1673-1676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27346676/pubmed" id="27346676" target="_blank">27346676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27983747">
<a name="27983747"></a>Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. <i>Pharmacotherapy</i>. 2017;37(2):236-248. doi:10.1002/phar.1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27983747/pubmed" id="27983747" target="_blank">27983747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916798">
<a name="30916798"></a>Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. <i>Am J Hematol</i>. 2019;94(6):697-709. doi:10.1002/ajh.25475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30916798/pubmed" id="30916798" target="_blank">30916798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33963877">
<a name="33963877"></a>Daei M, Khalili H, Heidari Z. Direct oral anticoagulant safety during breastfeeding: a narrative review.<i> Eur J Clin Pharmacol</i>. 2021;77(10):1465-1471. doi:10.1007/s00228-021-03154-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/33963877/pubmed" id="33963877" target="_blank">33963877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081965">
<a name="28081965"></a>Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. <i>J Am Coll Cardiol</i>. 2017;69(7):871-898. doi:10.1016/j.jacc.2016.11.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/28081965/pubmed" id="28081965" target="_blank">28081965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27919873">
<a name="27919873"></a>Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. <i>Am J Health Syst Pharm</i>. 2016;73(24):2037-2041. doi:10.2146/ajhp150596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27919873/pubmed" id="27919873" target="_blank">27919873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30191509">
<a name="30191509"></a>Fazio G, Dentamaro I, Gambacurta R, Alcamo P, Colonna P. Safety of edoxaban 30 mg in elderly patients with severe renal impairment. <i>Clin Drug Investig</i>. 2018;38(11):1023-1030. doi:10.1007/s40261-018-0693-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30191509/pubmed" id="30191509" target="_blank">30191509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Cardiovascular and Renal Drugs Advisory Committee briefing document: Savaysa (edoxaban tosylate). <a href="https://wayback.archive-it.org/7993/20170405211245/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420705.pdf" target="_blank">https://wayback.archive-it.org/7993/20170405211245/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420705.pdf</a>. September 26, 2014. Accessed April 24, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frost.1">
<a name="Frost.1"></a>Frost C, et al. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. <i>Clin Pharmacol Drug Dev</i>. 2013;2(1):19.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaasch.1">
<a name="Gaasch.1"></a>Gaasch WH, Konkle BA. Antithrombotic therapy for surgical prosthetic heart valves and surgical valve repair: Indications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29433148">
<a name="29433148"></a>Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. <i>Thromb Haemost</i>. 2018;118(3):437-450. doi: 10.1055/s-0038-1627480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/29433148/pubmed" id="29433148" target="_blank">29433148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24251359">
<a name="24251359"></a>Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med</i>. 2013;369(22):2093-2104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/24251359/pubmed" id="24251359" target="_blank">24251359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28050755">
<a name="28050755"></a>Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). <i>J Thromb Thrombolysis</i>. 2017;43(3):343-351. doi: 10.1007/s11239-016-1465-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/28050755/pubmed" id="28050755" target="_blank">28050755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324838">
<a name="26324838"></a>Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/26324838/pubmed" id="26324838" target="_blank">26324838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26022637">
<a name="26022637"></a>Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/26022637/pubmed" id="26022637" target="_blank">26022637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21750584">
<a name="21750584"></a>Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney Int</i>. 2011;80(6):572-586. doi: 10.1038/ki.2011.223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/21750584/pubmed" id="21750584" target="_blank">21750584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23991658">
<a name="23991658"></a>Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>N Engl J Med</i>. 2013;369(10):1406-1415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/23991658/pubmed" id="23991658" target="_blank">23991658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.1">
<a name="Hull.1"></a>Hull RD, Lip G. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. <i>Circulation</i>. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27207971">
<a name="27207971"></a>Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>J Am Heart Assoc</i>. 2016;5(5):e003432. doi:10.1161/JAHA.116.003432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27207971/pubmed" id="27207971" target="_blank">27207971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in <i>Chest</i>. 2016;150(4):988]. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi: 10.1200/JCO.19.01461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176890">
<a name="32176890"></a>Khan SU, Osman M, Khan MU, et al. Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Ann Intern Med</i>. 2020;172(7):474-483. doi: 10.7326/M19-3763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/32176890/pubmed" id="32176890" target="_blank">32176890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30396779">
<a name="30396779"></a>Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. <i>Surg Obes Relat Dis</i>. 2018;14(12):1890-1896. doi: 10.1016/j.soard.2018.08.025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30396779/pubmed" id="30396779" target="_blank">30396779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28121368">
<a name="28121368"></a>Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. <i>Br J Clin Pharmacol</i>. 2017;83(7):1466-1475. doi: 10.1111/bcp.13243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/28121368/pubmed" id="28121368" target="_blank">28121368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30036784">
<a name="30036784"></a>Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. <i>Thromb Res</i>. 2018;169:123-127. doi:10.1016/j.thromres.2018.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30036784/pubmed" id="30036784" target="_blank">30036784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30546740">
<a name="30546740"></a>Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. <i>J Cardiol Cases</i>. 2013;8(1):e49-e50. doi: 10.1016/j.jccase.2013.03.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30546740/pubmed" id="30546740" target="_blank">30546740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leung.1">
<a name="Leung.1"></a>Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. Post TW, ed. <i>UpToDate</i>. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 2, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885997">
<a name="32885997"></a>Levito MN, Coons JC, Verrico MM, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. <i>Ann Pharmacother</i>. Published online September 4, 2020. doi:10.1177/1060028020956271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/32885997/pubmed" id="32885997" target="_blank">32885997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lip.1">
<a name="Lip.1"></a>Lip G, Hull RD. Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30144419">
<a name="30144419"></a>Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. <i>Chest</i>. 2018;154(5):1121-1201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30144419/pubmed" id="30144419" target="_blank">30144419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lixiana.1">
<a name="Lixiana.1"></a>Lixiana (edoxaban) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manning.1">
<a name="Manning.1"></a>Manning WJ, Singer DE, Lip GYH. Atrial fibrillation in adults: use of oral anticoagulants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27299806">
<a name="27299806"></a>Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016; 14(6):1308-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/27299806/pubmed" id="27299806" target="_blank">27299806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865374">
<a name="32865374"></a>Okumura K, Akao M, Yoshida T, et al.; ELDERCARE-AF Committees and Investigators. Low-dose edoxaban in very elderly patients with atrial fibrillation.<i> N Engl J Med</i>. 2020;383(18):1735-1745. doi:10.1056/NEJMoa2012883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/32865374/pubmed" id="32865374" target="_blank">32865374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31624780">
<a name="31624780"></a>Othman M, Santamaría Ortiz A, Cerdá M, et al. Thrombosis and hemostasis health in pregnancy: registries from the International Society on Thrombosis and Haemostasis. <i>Res Pract Thromb Haemost</i>. 2019;3(4):607-614. doi:10.1002/rth2.12243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/31624780/pubmed" id="31624780" target="_blank">31624780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25566930">
<a name="25566930"></a>Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. <i>Thromb Haemost</i>. 2015;113(4):719-727. doi: 10.1160/TH14-06-0547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/25566930/pubmed" id="25566930" target="_blank">25566930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29367334">
<a name="29367334"></a>Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in: <i>Stroke</i>. 2018;49(3):e138.]. <i>Stroke</i>. 2018;49(3):e46-e110. doi: 10.1161/STR.0000000000000158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/29367334/pubmed" id="29367334" target="_blank">29367334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231094">
<a name="29231094"></a>Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism [published online ahead of print December 12, 2017]. <i>N Engl J Med</i>. doi: 10.1056/NEJMoa1711948.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/29231094/pubmed" id="29231094" target="_blank">29231094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28167634">
<a name="28167634"></a>Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in <i>Circulation</i>. 2017;135(10):e647; <i>Circulation</i>. 2017;135(24):e1144]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/28167634/pubmed" id="28167634" target="_blank">28167634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29157916">
<a name="29157916"></a>Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thromb Res</i>. 2018;163:190-195. doi: 10.1016/j.thromres.2017.11.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/29157916/pubmed" id="29157916" target="_blank">29157916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30719364">
<a name="30719364"></a>Sakai M, Ogura J, Yamanoi K, et al. A case of pregnancy complicated with ATIII deficiency in a patient who developed severe venous thromboembolism in her fourth pregnancy and had a favourable outcome in her subsequent pregnancy with careful management of anticoagulation therapy including edoxaban. <i>Case Rep Obstet Gynecol</i>. 2019;2019:2436828.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/30719364/pubmed" id="30719364" target="_blank">30719364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Savaysa.1">
<a name="Savaysa.1"></a>Savaysa (edoxaban) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31076635">
<a name="31076635"></a>Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase<sup>®</sup>. <i>Sci Rep</i>. 2019;9(1):7236. doi:10.1038/s41598-019-43715-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/31076635/pubmed" id="31076635" target="_blank">31076635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31492505">
<a name="31492505"></a>Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet</i>. 2019;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edoxaban-drug-information/abstract-text/31492505/pubmed" id="31492505" target="_blank">31492505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xarelto.1">
<a name="Xarelto.1"></a>Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 99275 Version 224.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
